Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the "Company") was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market ("Nasdaq") and the Company had until May 11, 2026, which was the maximum extent of the discretionary authority of the Nasdaq Hearings Panel (the "Panel").

Having not regained compliance with the Bid Price Requirement by such date, the Company received a letter from the Panel dated May 12, 2026 indicating that the Panel had determined to delist the Company's common stock from Nasdaq. The Company's common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026.

Beginning on May 14, 2026, the Company's common stock will be quoted on the OTCQB Venture Market operated by OTC Markets Group Inc. under its existing symbol "RVPH."